Arbutus Biopharma Corp
NASDAQ:ABUS
Arbutus Biopharma Corp
NASDAQ:ABUS
Price:
2.69 USD
-1.47%
Market Closed
Updated:
May 2, 2024
Arbutus Biopharma Corp
Revenue
|
Arbutus Biopharma Corp
Revenue Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
Revenue
$18.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
25%
|
CAGR 10-Years
2%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Arbutus Biopharma Corp
Revenue Breakdown
Breakdown by Geography
Arbutus Biopharma Corp
Arbutus Biopharma Corp
Not Available
Breakdown by Segments
Arbutus Biopharma Corp
Arbutus Biopharma Corp
|
Total Revenue:
18.1m
USD
|
|
Collaborations And Licenses:
14.3m
USD
|
|
Non-Cash Royalty Revenue:
3.9m
USD
|
See Also
What is Arbutus Biopharma Corp's Revenue?
Revenue
18.1m
USD
18.1m
USD
Based on the financial report for Dec 31, 2023, Arbutus Biopharma Corp's Revenue amounts to 18.1m USD.
What is Arbutus Biopharma Corp's Revenue growth rate?
Revenue CAGR 10Y
2%
2%
Over the last year, the Revenue growth was -54%. The average annual Revenue growth rates for Arbutus Biopharma Corp have been 38% over the past three years , 25% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
